ANTIGENICS INC. SECURITIES EXCHANGE AGREEMENTSecurities Exchange Agreement • August 10th, 2009 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • New York
This Securities Exchange Agreement (this “Agreement”) is made as of June 4, 2009 (the “Effective Date”) by and between ANTIGENICS INC., a Delaware corporation (the “Company”), and The Wolverine Convertible Arbitrage Fund Trading Limited (the “Bond Holder”).
Amendment No. 2 to Master Services AgreementMaster Services Agreement • August 10th, 2009 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Massachusetts
This Amendment Number Two (this “Amendment 2”) is entered into this 22nd day of April, 2009 (the “Amendment 2 Effective Date”), by and between Antigenics Inc., a Delaware corporation having an address at 162 Fifth Avenue, Suite 900, New York, New York 10010 (the “Company”) and Raifarm Limited, a Cyprus registered company, having an address at Cyprus- Limassol 3030, 35 Thekla Lysioti street Eagle Star House, 6th floor, (each a “Party” and collectively the “Parties”). Capitalized terms not otherwise defined shall have the meaning set forth in the Agreement.
AMENDMENT – NUMBER TWO LICENSE AGREEMENTLicense Agreement • August 10th, 2009 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Connecticut
This Amendment Number Two (this “Amendment 2”) is entered into this 5th day of June, 2009 by and between the UNIVERSITY OF CONNECTICUT HEALTH CENTER, having a place of business at the Center for Science and Technology Commercialization, 263 Farmington Avenue, Farmington, Connecticut 06030-6207 (“UCONN”), and ANTIGENICS INC., having offices at 3 Forbes Road, Lexington, Massachusetts 02421 (“ANTIGENICS”) (each a “Party” and collectively, the “Parties”).
ANTIGENICS INC. SECURITIES EXCHANGE AGREEMENTSecurities Exchange Agreement • August 10th, 2009 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • New York
This Securities Exchange Agreement (this “Agreement”) is made as of June 4, 2009 (the “Effective Date”) by and between ANTIGENICS INC., a Delaware corporation (the “Company”), and The Conus Fund L.P. (the “Fund”), The Conus Fund Offshore Master Fund Ltd. (the “Offshore Fund”), The Conus Fund (QP) L.P. (the “QP Fund”) (collectively, the Fund, the Offshore Fund and the QP Fund are referred to herein as the “Bond Holder”).
May 11, 2009 Michael F. Newborg, Executive Director University of Connecticut Health Center Center for Science and Technology CommercializationAntigenics Inc /De/ • August 10th, 2009 • Biological products, (no disgnostic substances)
